Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the third quarter.
Let’s start with the continued — and very necessary — push to develop medicines and vaccines against the novel coronavirus. There has already been a lot written about the experimental mRNA-based vaccine Moderna is developing, for which it currently hasn’t disclosed specific data. That should change relatively soon with the publication of the Phase 1 study results in a scientific journal.
About the Author Reprints
